Certara (NASDAQ:CERT) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Certara (NASDAQ:CERT) from a hold rating to a buy rating in a research report report published on Saturday.

Other equities analysts also recently issued research reports about the stock. Rothschild & Co Redburn set a $10.00 price objective on shares of Certara in a report on Friday, November 21st. Stephens dropped their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, December 12th. Leerink Partners upgraded Certara from a “market perform” rating to an “outperform” rating and set a $13.00 price objective for the company in a research note on Tuesday, January 6th. Barclays decreased their target price on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. Finally, Morgan Stanley cut their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.82.

Certara Price Performance

NASDAQ CERT opened at $7.23 on Friday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 103.29 and a beta of 1.47. Certara has a 1-year low of $7.16 and a 1-year high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The business’s fifty day moving average price is $9.06 and its 200-day moving average price is $10.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. The company had revenue of $104.62 million during the quarter, compared to analyst estimates of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same quarter in the previous year, the company posted $0.13 earnings per share. On average, equities analysts predict that Certara will post 0.28 earnings per share for the current year.

Institutional Trading of Certara

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Associated Banc Corp increased its stake in Certara by 9.7% during the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after purchasing an additional 1,051 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Certara by 2.5% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after buying an additional 1,136 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Certara by 66.7% in the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the period. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the period. Finally, ANTIPODES PARTNERS Ltd raised its stake in Certara by 22.5% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock worth $78,000 after acquiring an additional 1,223 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.